Novo Nordisk Faces Double Departures: GLP-1 Expert Retires as Obesity Leader Joins Boehringer Ingelheim
Search results do not contain specific information on recent news about 'Novo's double departures' involving a GLP-1 luminary retiring and an obesity leader moving to Boehringer Ingelheim.
Results focus instead on GLP-1 drug studies, including cardiovascular risks from discontinuation 1, switching medications for better adherence 3, clinical trials 2, and drug shortages 4.
No direct mentions of personnel changes at Novo Nordisk or moves to Boehringer Ingelheim in the provided sources.
Sources:
1. https://medicine.washu.edu/news/stopping-glp-1-drugs-can-quickly-erase-cardiovascular-benefits/
2. https://cdn.clinicaltrials.gov/large-docs/77/NCT04667377/Prot_000.pdf
3. https://www.utsouthwestern.edu/newsroom/articles/year-2026/march-glp-1-medication-weight-management.html